Search Results

You are looking at 51 - 60 of 73 items for :

  • "zoledronic acid" x
Clear All
Full access

R. Michael Tuttle, Robert I. Haddad, Douglas W. Ball, David Byrd, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, William M. Lydiatt, Judith McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann and Miranda Hughes

denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma . J Clin Oncol 2011 ; 29 : 1125 – 1132 . 76 Rosen LS Gordon D Tchekmedyian NS

Full access

Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb and William I. Gradishar

–releasing hormone (LHRA) with zoledronic acid, at least in patients with node-negative disease. Justification: Results of the ABCSG-12 study showed 94% survival in patients treated with hormonal therapy alone. 31 Systemic Adjuvant Treatment: Hormone

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Sam Bhayani, William P. Bro, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Mayer Fishman, Thomas H. Gallagher, John L. Gore, Steven L. Hancock, Michael R. Harrison, Won Kim, Christos Kyriakopoulos, Chad LaGrange, Elaine T. Lam, Clayton Lau, M. Dror Michaelson, Thomas Olencki, Phillip M. Pierorazio, Elizabeth R. Plimack, Bruce G. Redman, Brian Shuch, Brad Somer, Guru Sonpavde, Jeffrey Sosman, Mary Dwyer and Rashmi Kumar

of bone-modifying agents such as bisphosphonates (eg, zoledronic acid) has been well-established in this setting. 206 , 207 The newer bone-modifying agent approved for use in patients with RCC that has metastasized to bone is the RANK-L inhibitor

Full access

Jill R. Tichy, Elgene Lim and Carey K. Anders

addition to evaluating the effects of adding zoledronic acid to adjuvant endocrine therapy, the Austrian Breast Cancer Study Group (ABCSG) XII compared tamoxifen plus goserelin versus anastrozole plus goserelin in early-stage, premenopausal, hormone

Full access

Amelia B. Zelnak and Ruth M. O'Regan

-12) was a smaller study of 1803 premenopausal women with HR-positive breast cancer randomized to either anastrozole plus ovarian suppression or tamoxifen plus ovarian suppression, with or without zoledronic acid. In contrast to the combined analysis

Full access

Victor T.G. Lin, Lisle M. Nabell, Sharon A. Spencer, William R. Carroll, Shuko Harada and Eddy S. Yang

was identified. After discussion by the UAB MTB, 1 he was started on targeted therapy with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib, in addition to zoledronic acid for his bony metastases ( Figure 1 ). Dabrafenib and trametinib

Full access

Philip L. McCarthy

Morgan GJ Davies FE Gregory WM . First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial . Lancet 2010 ; 376 : 1989 – 1999 . 41 Mailankody S Pfeiffer RM

Full access

Christos Vaklavas, John R. Ross, Lisle M. Nabell, Andres Forero, Martin J. Heslin and Tina E. Wood

anastrozole and zoledronic acid while considering chemotherapy when her gastrointestinal malignancies become symptomatic or meta-static. Early-stage signet-ring cell gastric carcinoma usually has a favorable prognosis (5-year survival rate of 94.3%), 2 but

Full access

Jay Gong, Jeffrey P. Gregg, Weijie Ma, Ken Yoneda, Elizabeth H. Moore, Megan E. Daly, Yanhong Zhang, Melissa J. Williams and Tianhong Li

10 fractions. The patient also received zoledronic acid first and then denosumab for approximately 2 years to prevent fracture, spinal cord compression, or the need for RT. Figure 1. Radiographic imaging, histomorphology, and immunohistochemical

Full access

Marina Deuker, Giuseppe Rosiello, Lara Franziska Stolzenbach, Thomas Martin, Claudia Collà Ruvolo, Luigi Nocera, Zhe Tian, Frederik C. Roos, Andreas Becker, Luis A. Kluth, Derya Tilki, Shahrokh F. Shariat, Fred Saad, Felix K.H. Chun and Pierre I. Karakiewicz

-controlled trial of zoledronic acid in bony metastatic bladder cancer . Int J Clin Oncol 2010 ; 15 : 382 – 389 . 10.1007/s10147-010-0074-5 20354750 16. Raman JD , Messer J , Sielatycki JA , . Incidence and survival of patients with carcinoma of the